Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us
Become a catalyst

For investors

Investors have the power to influence companies to take action for global health. Armed with the Foundation’s analyses and insights, investors can make informed decisions and steward investee companies towards both sustainability and prosperity. Besides providing tailored advice on access-to-medicine topics, we also generate opportunities for collaborative action.

Avanti Gupta

Investor Engagement Manager

Get in touch

Direct links

IAAMR Investor Statement

Covid-19 Investor statement

Access to Medicine Index Investor Statement

Avanti Gupta

Investor Engagement Manager

Get in touch

Signatory investors gain a whole host of benefits, including:

  • Direct access to our 10+ analysts who track company activities on a daily basis 

  • Unique analyses and insights on sector-specific ESG risks and opportunities 

  • Regular updates on key developments in global health

  • Participation in collaborative engagements that drive and track company progress

  • Access to investor events and opportunities for networking and knowledge-sharing

  • Participation in methodology development for the Access to Medicine Index and Antimicrobial Resistance Benchmark

The Foundation is committed to providing its data and analyses free of charge to all stakeholder groups, including investors.

Read our investor statement here.

BECOME A SIGNATORY INVESTOR

Join our opportunities for collaborative action

Investors are strongest when they pool their influence. By joining the Foundation's collaborative initiatives, investors can jointly steer investee companies to do better.

SDG3 Collaborative Engagement

This unique opportunity allows investors to collectively drive pharma companies toward the achievement of the UN’s Sustainable Development Goal 3: to ensure healthy lives and promote well-being for all at all ages. This long-term investor-led engagement uses the Access to Medicine Index to drive and track pharmaceutical company progress and impact on increased access to medicine in LMICs. To date, over 145 investors managing assets of more than USD 22 trillion have committed to use our data and insights. Read our investor statement here.

Investor Action on Antimicrobial Resistance (IAAMR)

This initiative was launched in 2020 by the Access to Medicine Foundation, the FAIRR initiative, the Principles for Responsible Investment and the UK Government’s Department of Health and Social Care, to focus on the role of capital markets in tackling the global threat of rising drug-resistant infections.

Ahead of the UN General Assembly’s second-ever High-Level Meeting on AMR in September, the IAAMR launched an Investor Statement calling on global leaders and policymakers to combat AMR. It includes seven critical requests, spotlighting solutions to the AMR crisis. The Statement, which was open for signing until 31 December 2024, sought to galvanise investor efforts to address AMR – with a total of 89 investors managing USD 13.9 trillion, signing the Statement.

Read more about AMR-related risks and opportunities for investors as published on AMR Action & Insights.

Covid 19 Investor statement

Read the global investor statement in support of an effective, fair and equitable global response to Covid-19

Download

Investor statement targets global action on AMR

Read the IAAMR Investor Statement

Download

Pharmaceutical companies have human rights responsibilities in relation to access to medicines. Part of this responsibility relies on the companies’ capacity to ensure that essential products and services reach out patients, and especially, most vulnerable patients, including groups such as children, pregnant women and minorities. In other words, pharmaceutical companies shall identify and assess the needs, vulnerabilities and obstacles to access, implement access plans and strategies with specific measures to ensure patients are effectively reached, adopt indicators to monitor the effectiveness of their policies, be transparent about their programmes and results, and – last, but not least – consult with relevant stakeholders throughout the process. Patient reach is also a material issue for these companies, as in the long-term, prioritizing patient reach will also drive innovation and widen product availability. More robust and transparent patient reach strategies, with clear and defined frameworks and indicators, as presented in Access to Medicine Foundation’s last report, will help investors tracking companies’ performance, both in terms of human rights and materiality, and facilitate investors’ capacity to assess and monitor companies’ strategies, policies and results.

Camille Bisconte de Saint Julien

Human Rights and Social Analyst and Direction Solutions ISR, La Banque Postale Asset Management (LBP AM)

Who is on board?

Leading investors use the Access to Medicine Index

More than 145 institutional investors, accounting for a total of USD 22 trillion in assets under management, use our research to aid in the investment decision-making processes.

Investors play a vital role in improving access to medicine 

Issues of access to medicine in low- and middle-income countries can present potentially significant business impacts for essential healthcare companies. By encouraging systematic action to improve access, investors can guide investee companies towards a more sustainable profile. This is vital for the long-term commercial success and viability of companies, as emerging markets and ESG considerations become ever more important.

At the Access to Medicine Foundation, we recognise the power of investors to spur positive progress towards global healthcare equity. Our independent research and data-driven insights provide input for investment decisions, while our investor engagement team are on hand to offer tailored advice and facilitate collaboration.

2022 Access to Medicine Index investor launch event co-hosted by Goldman Sachs in London (November 2022)

2022 Access to Medicine Index investor launch event co-hosted by Goldman Sachs in London (November 2022)

2022 Access to Medicine Index investor launch event co-hosted by Deloitte in Tokyo (December 2022)

2022 Access to Medicine Index investor launch event co-hosted by Deloitte in Tokyo (December 2022)

Bram Wagner, Investor Engagement Officer, speaking at the Generic & Biosimilar Medicines Programme: Company Profiles investor launch event, co-hosted by Nomura Asset Management (October 2023, Amsterdam)

Bram Wagner, Investor Engagement Officer, speaking at the Generic & Biosimilar Medicines Programme: Company Profiles investor launch event, co-hosted by Nomura Asset Management (October 2023, Amsterdam)

Suzi van Es, Investor Engagement Manager, speaking on a panel discussion on 'Antibiotic resistance: What role do investors have in addressing this systemic societal risk?’ at Responsible Investor Europe 2023 (June 2023, London)

Suzi van Es, Investor Engagement Manager, speaking on a panel discussion on 'Antibiotic resistance: What role do investors have in addressing this systemic societal risk?’ at Responsible Investor Europe 2023 (June 2023, London)

Bram Wagner, Investor Engagement Officer, speaking on a panel discussion on 'Global Health Challenges Can investors and civil society work together' hosted by the Geneva Graduate Institute and the Global Health Centre (October 2023, Geneva)

Bram Wagner, Investor Engagement Officer, speaking on a panel discussion on 'Global Health Challenges Can investors and civil society work together' hosted by the Geneva Graduate Institute and the Global Health Centre (October 2023, Geneva)

How we engage with the investor community

Our investor engagement team helps institutional investors to use the Foundation’s findings and analysis to better manage risks and opportunities for essential healthcare companies. We analyse financially material topics for the industry, including how essential healthcare companies approach governance, R&D, pricing and intellectual property management. 

Through our Access to Medicine Index and Antimicrobial Resistance Benchmark, we identify best practices, evaluate company performances and assess industry trends. We regularly publish reports that cover profitable business lines, such as oncology and cardiovascular health, as well as global health priorities such as infectious diseases, including COVID-19. 

Investors use our data in various ways, including integrating findings into quantitative models and qualitative company assessments, as well as in their interactions with companies. Our team interacts regularly with investors to provide tailored advice and analysis as needed to inform investment decisions. We also help investors to engage essential healthcare companies through roundtable discussions, research launches, collective calls to action and collaborative engagements.

Bram Wagner, Investor Engagement Officer, on healthcare investing through the lens of accessibility on Ninety Nine podcast

Read more

Calls to action from the investor community

A number of our signatories have outlined the value they see in Access to Medicine Index and the Antimicrobial Resistance Benchmark, and why investors should engage:

  • Australian Ethical: "Access to Medicine: The issue, the Foundation, and the investor call-to-action." Read more.  

  • Candriam Investors: "Access to medicines, or how equality has become a central issue for pharma businesses." Read more.

  • Coho Partners: "ESG Insights: The Pandemic, Vaccines, and the importance of Access to Medicine." Read more. 

  • Ecofi: "Pharmaceutical companies and access to medicines: what role for investors?'' Read more. 

  • Janus Henderson: ''Access to medicine - the need for innovation, partnerships and data capture.'' Read more. 

  • Rathbone Greenbank Investments: "Antibiotics: Preserving the miracle cure". Read more.

It is up to the investment community to hold [pharma] companies accountable...and to challenge companies over whether they are doing enough to ensure their products are reaching as many people as possible.

Janus Henderson Investors

May 2021

Resource centre

Explore our latest research and publications
Media

AMR-related risks and opportunities for investors

02 April 2025
Research

Health & Wealth: The Investors’ Guide to Antimicrobial Resistance (AMR), a Growing Global Health Crisis

27 August 2024
Media

How investors can bolster global health equity while generating long-term value

12 February 2024

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved